Compare SLNG & NBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SLNG | NBP |
|---|---|---|
| Founded | 2013 | 2014 |
| Country | United States | United States |
| Employees | N/A | 30 |
| Industry | Oil/Gas Transmission | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 97.4M | 96.0M |
| IPO Year | 2019 | 2019 |
| Metric | SLNG | NBP |
|---|---|---|
| Price | $3.81 | $0.83 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $8.67 |
| AVG Volume (30 Days) | 18.4K | ★ 497.4K |
| Earning Date | 11-04-2026 | 08-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $68,245,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $73.32 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.21 | $0.82 |
| 52 Week High | $7.07 | $5.19 |
| Indicator | SLNG | NBP |
|---|---|---|
| Relative Strength Index (RSI) | 36.86 | 17.74 |
| Support Level | $3.69 | N/A |
| Resistance Level | $4.44 | $1.45 |
| Average True Range (ATR) | 0.30 | 0.08 |
| MACD | -0.00 | -0.02 |
| Stochastic Oscillator | 43.65 | 3.39 |
Stabilis Solutions Inc is an energy transition company that provides turnkey clean energy production, storage, transportation, and fueling solutions using liquefied natural gas (LNG) to multiple end markets. The company provides LNG solutions to customers in diverse end markets, including aerospace, agriculture, energy, industrials, marine bunkering, mining, pipeline, remote power, and utility markets. It generates revenue by selling and delivering LNG to its customers, renting cryogenic equipment, and providing engineering and field support services. The company has a geographical presence in the United States and Mexico.
NovaBridge Biosciences operates as a biotechnology platform, combining business development and clinical research to identify and advance pharmaceutical assets. Its inventive immuno-oncology pipeline consists of three clinical stage programs, givastomig; uliledlimab; and ragistomig. Its core product, givastomig, is a potential in-class CLDN18.2 bispecific antibody for the treatment of gastric cancer and other CLDN18.2-positive gastrointestinal malignancies.